One of the most talked about treatments for rheumatoid arthritis (RA) involves the use of disease-modifying antirheumatic drugs or DMARDs. Studies show these medications can actually halt the ...

Please provide your email address to receive an email when new articles are posted on . Despite guidelines recommending early and aggressive therapy in RA, disease-modifying antirheumatic drug ...

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) than in patients who ...

Minimal disease activity (MDA) was more likely in people with psoriatic arthritis (PsA) when they initiated a disease-modifying anti-rheumatic drug (DMARD) earlier rather than later. That's according ...

The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...

Relapse occurred in over half of patients with juvenile idiopathic arthritis (JIA) within a year of stopping biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) treatment after ...

A new study led by researchers at Queen Mary University of London provides potential novel biomarkers for predicting patient responsiveness to disease-modifying anti-rheumatic drugs (DMARDs).

Etanercept can bind to and neutralize extracellular tumor necrosis factor, and has proven clinical efficacy in reducing the disease symptoms of patients with rheumatoid arthritis (RA) who cannot ...